ARHGEF3 / Rho guanine nucleotide exchange factor 3 · IHC design guide

Design Immunohistochemistry for ARHGEF3

Plan ARHGEF3 paraffin-section IHC around the reported nuclear tissue staining (HPA tissue IHC) and its cytoplasmic annotation (UniProt). Compare positive cell populations carefully because staining and RNA expression show low consistency (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for ARHGEF3 (IHC for ARHGEF3): expected localisation Nuclear staining in tissue (HPA tissue IHC); cytoplasmic annotation (UniProt), antibody A09012-1, validated IHC image, and IHC protocol steps — Printable **ARHGEF3** IHC protocol sheet — expected localisation Nuclear staining in tissue (HPA tissue IHC); cytoplasmic annotation (UniProt), antibody A09012-1, controls and protocol steps. Open the full ARHGEF3 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

ARHGEF3 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Nuclear staining in tissue (HPA tissue IHC); cytoplasmic annotation (UniProt)
	Staining pattern	Nuclear staining in glandular, hematopoietic and neuronal cells (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A09012-1)
	Positive control ⓘ	Appendix+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep paraffin-section fixation consistent. (standard IHC practice; not target-specific)
	Caveat	Tissue staining has low consistency with RNA expression (HPA tissue IHC)
	Regulation	Widely expressed; regulation unspecified (UniProt)
	Isoform / epitope	4 isoforms; variant epitope coverage is unknown (UniProt)

Section 1

Recommended ARHGEF3 IHC & IF Protocols

Compare the catalog antibody’s IHC-P protocol (datasheet A09012-1) with a published ARHGEF3 protocol for nasopharyngeal carcinoma tissue microarrays (PMC5041948).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human tonsil tissue; fixative not specified (datasheet A09012-1)
Fixation	Image fixative and duration unreported (datasheet A09012-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Tris-EDTA pH 9.0 (datasheet A09012-1); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-ARHGEF3, 1:50 recommended; image 1:200 (datasheet A09012-1)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	ARHGEF3-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in all tissues. No signal in the no-primary control.

💡Decision noteStart with Tris-EDTA pH 9.0 heat retrieval for the catalog antibody (datasheet A09012-1); try citrate pH 6.0 for the published tissue microarray conditions (PMC5041948).

Section 2

What Is the Expected ARHGEF3 Staining Pattern?

ARHGEF3 is a cytoplasmic protein with no transmembrane segment (UniProt Q9NR81). Cytosolic signal is also supported by approved ICC-IF localisation (HPA: cytosol, approved). In paraffin IHC, examine the named cells in HPA high-staining tissues, including appendix glandular cells and cerebral cortex neuronal cells (HPA: High). HPA reports nuclear staining across tissues, but rates its tissue IHC pattern Uncertain because antibody staining and RNA data have low consistency (HPA: IHC Uncertain).

What am I looking at on my slide?
Cytoplasmic staining in appendix glandular cells or cerebral cortex neuronal cells.	This fits the reported protein compartment and named high-staining cells (UniProt Q9NR81: cytoplasm; HPA: cytosol approved; HPA: High in these cells). Interpret the slide alongside controls: HPA's tissue IHC reliability remains Uncertain, so a matching appearance alone does not establish antibody specificity (HPA: IHC Uncertain).
Predominantly nuclear staining, especially when it appears across many cell types.	Treat this as a discordant compartment and investigate a possible staining artefact (UniProt Q9NR81: cytoplasm; HPA: cytosol approved). HPA does report nuclear expression in all tissues, but labels that tissue IHC pattern Uncertain; nuclear signal therefore needs independent confirmation before it is assigned to ARHGEF3 (HPA: tissue IHC).
Strong signal in adipocytes while the expected glandular or neuronal cells show little staining.	Adipocytes are listed as low-staining, whereas appendix glandular and cerebral cortex neuronal cells are High (HPA: tissue IHC). Check cell identification and controls; an inverted pattern can reflect cross-reactivity or endogenous detection activity (general IHC practice). HPA's Uncertain IHC rating limits how firmly any one tissue comparison can establish specificity (HPA: IHC Uncertain).
Diffuse colour across cells, stroma, and the empty areas of a section.	A pattern without clear cellular boundaries cannot be scored as ARHGEF3 localisation (general IHC practice). Check whether the same colour appears in a no-primary control, and review blocking, washes, and chromogen development before comparing tissue staining levels (general IHC practice).
No discernible signal in the named high-staining cells of an otherwise interpretable section.	First check the positive control and detection workflow (general IHC practice). HPA lists several high-staining cell populations, but its tissue IHC reliability is Uncertain; an HPA High call is a useful comparison, not a guarantee that every section or antibody run will stain (HPA: tissue IHC).

💡Expected ARHGEF3 appearanceA supported positive result is discernible cytoplasmic colour in named HPA High cells, such as appendix glandular or cerebral cortex neuronal cells; widespread nuclear-only or structure-free diffuse colour warrants investigation (UniProt Q9NR81: cytoplasm; HPA: cytosol approved; HPA: tissue IHC Uncertain; general IHC practice).

How each factor affects the staining
Compartment evidence	UniProt places ARHGEF3 in the cytoplasm, and HPA approves cytosolic ICC-IF localisation (UniProt Q9NR81; HPA: ICC-IF approved). HPA's nuclear tissue IHC profile has Uncertain reliability, so the two observations should be reported separately rather than merged into a single expected compartment (HPA: tissue IHC).
Tissue and cell selection	HPA calls appendix glandular, bone marrow hematopoietic, and cerebral cortex neuronal cells High, while adipocytes and soft-tissue fibroblasts are Low (HPA: tissue IHC). These provide relative staining comparisons; HPA reports low tissue RNA specificity and an Uncertain IHC profile, so neither group is an absolute positive or negative control (HPA: tissue IHC).
Antibody evidence	The listed tissue IHC antibody HPA034715 is rated Uncertain, whereas HPA064945 is approved for ICC-IF and has no supplied IHC rating (HPA: antibody validation). An ICC-IF approval cannot establish performance of a paraffin IHC assay; assess the IHC-validated antibody and its controls in the intended detection workflow (general IHC practice).
Protein form and epitope	UniProt lists 4 isoforms, a 1–526 chain, no signal peptide or propeptide, and no transmembrane segment (UniProt Q9NR81). No epitope location or isoform-specific staining evidence is supplied; these sequence facts cannot predict which isoforms an antibody detects or justify a processing-related tissue pattern.
Detection chemistry	In chromogenic IHC, endogenous enzyme activity can produce colour independent of primary-antibody binding (general IHC practice). A no-primary control helps identify that contribution; it does not resolve whether primary-dependent staining comes from ARHGEF3 or another bound antigen (general IHC practice).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Nuclear colour dominates while cytoplasm is faint.	The slide conflicts with UniProt cytoplasmic and HPA approved cytosolic localisation, although HPA reports an Uncertain nuclear tissue IHC pattern (UniProt Q9NR81; HPA: ICC-IF approved; HPA: IHC Uncertain).	Check the no-primary control and nuclear counterstain, then verify any primary-dependent nuclear pattern with independent specificity evidence before calling it ARHGEF3 (general IHC practice).
Adipocytes stain more strongly than named High cell populations.	This reverses the supplied HPA contrast and may reflect mistaken cell assignment, cross-reactivity, or endogenous detection activity (HPA: adipocytes Low; HPA: selected glandular and neuronal cells High; general IHC practice).	Recheck morphology and compare matched controls and tissue compartments on the same run; report the discordance without treating HPA's Uncertain profile as a definitive exclusion rule (general IHC practice; HPA: IHC Uncertain).
Diffuse colour obscures cell boundaries.	Nonspecific reagent binding, insufficient washing, or excessive chromogen development can produce background in chromogenic IHC (general IHC practice).	Compare a no-primary section, review blocking and wash steps, and reduce detection development as appropriate; score only signal with identifiable cellular localisation (general IHC practice).
No signal appears in appendix glandular or cerebral cortex neuronal cells.	These cells are reported High by HPA, but a failed control, detection step, or antibody run can also yield a blank slide (HPA: tissue IHC; general IHC practice).	Confirm that an appropriate positive control stained, then review the catalog antibody's IHC-P instructions for retrieval and dilution and inspect the detection reagents (general IHC practice). No ARHGEF3-specific retrieval condition is supplied.
Colour appears on a no-primary section.	The colour does not require the primary antibody; endogenous detection activity or reagent background is possible (general IHC practice).	Address the detection system's endogenous-activity block and reagent background, then repeat the no-primary control before interpreting ARHGEF3 staining (general IHC practice).
A positive control stains, but the test section remains negative.	The control confirms that detection worked in that run, while the test section's cell composition or antigen signal may differ (general IHC practice). HPA's High categories do not guarantee staining in every specimen (HPA: IHC Uncertain).	Verify the expected cell population on the counterstained section and document the negative result with the control outcome; seek independent evidence before concluding that ARHGEF3 is absent (general IHC practice).

Source: UniProt Q9NR81 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing ARHGEF3 staining

Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 30min).

A09012-1 · IHCImmunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was use

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue/cerebral+cortex#imid_8420159

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue/colon#imid_8420083

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue/liver#imid_8420076

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue/kidney#imid_8420069

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA064945; green = ARHGEF3, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for ARHGEF3 IHC & IF

🧪Run bone marrow first: hematopoietic cells should stain (HPA: High in bone marrow hematopoietic cells). HPA detects ARHGEF3 in all 45 scored tissues, so use no-primary and isotype controls for the negative; within the positive slide, nuclei should lack specific cytoplasmic staining, but no cell population can be assumed negative (HPA: no negative tissue rows; UniProt Q9NR81: cytoplasm).

Positive control tissue: Appendix (Glandular cells, HPA High)

Negative control tissue: None in HPA: ARHGEF3 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF3 in A-431, Hep-G2, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only slide and an isotype control matched to the primary antibody’s host species, clonality, and concentration; use an ARHGEF3 knockout specimen as a biological negative if available. For bone marrow chromogenic IHC, block endogenous peroxidase and check background in the negative controls (HPA: bone marrow hematopoietic cells, High; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A09012-1 paraffin-section caption does not state the fixative. Start retrieval optimization with Tris-EDTA at pH 9.0 and the catalog antibody at 1:200, as reported for human tonsil; that caption does not establish whether retrieval is required in bone marrow (A09012-1 tissue-IHC caption). Frozen sections are not established as easier by the supplied evidence; IF/ICC has supporting cytosolic images in A-431, Hep-G2, and U2OS, while endogenous peroxidase is a relevant bone marrow artefact in chromogenic IHC (HPA: approved cytosol location and listed ICC-IF image cell lines; HPA: bone marrow hematopoietic cells, High; standard IHC practice).

HPA tissue IHC evidence for ARHGEF3

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Cerebral cortex	Neuronal cells	High	Protein (IHC)	HPA →
Cervix	Squamous epithelial cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: ARHGEF3 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced ARHGEF3 IHC Tips

Troubleshoot ARHGEF3 chromogenic IHC in paraffin sections by checking retrieval, compartment, controls and scoring; use IF as a secondary localisation check.

Which retrieval conditions should I start with for ARHGEF3 paraffin IHC?

Use heat-mediated Tris-EDTA at pH 9.0 for ARHGEF3 retrieval in paraffin sections (datasheet A09012-1). The selected tonsil image used this buffer, primary antibody at 1:200 overnight at 4°C, and secondary antibody at 1:200 for 30 minutes at room temperature (caption A09012-1). Keep heating and cooling conditions constant across specimens, and titrate retrieval duration against morphology and background before comparing intensity (standard IHC practice). Score retrieved cytoplasmic and nuclear staining separately because the protein is annotated cytoplasmic while tissue IHC reports uncertain nuclear staining (UniProt Q9NR81 subcellular; HPA tissue IHC).

How should I handle fixation when ARHGEF3 staining varies between specimens?

Target-specific fixation sensitivity for ARHGEF3 in paraffin IHC is unknown; the selected tonsil caption does not report a fixative (caption A09012-1). Record fixative type, fixation duration, tissue thickness and processing interval for each specimen, and compare sections prepared under matched conditions (standard IHC practice). Use a consistently processed control section in each staining run to help distinguish processing variation from changes in signal (standard IHC practice). If signal varies with preservation, compare matched serial sections and a processing control before assigning a biological explanation to the difference (standard IHC practice).

Where should ARHGEF3 chromogenic signal appear in paraffin sections?

Expect a predominantly cytoplasmic pattern when evaluating ARHGEF3, consistent with its UniProt annotation and approved cytosolic IF localisation (UniProt Q9NR81 subcellular; HPA subcellular). The tissue IHC profile instead reports nuclear expression across tissues, but its reliability is uncertain because staining and RNA expression have low consistency (HPA tissue IHC). Score cytoplasmic and nuclear deposits separately within annotated cell populations, and review a no-primary control for nuclear precipitate (standard IHC practice). High staining in cerebral cortex neuronal cells or bone marrow hematopoietic cells can guide control selection, but does not resolve compartment specificity (HPA tissue IHC: high; uncertain).

Could isoforms or epitope accessibility explain discordant ARHGEF3 staining?

ARHGEF3 has 4 annotated isoforms, so an antibody raised to an undisclosed sequence may not recognize each isoform equally (UniProt Q9NR81 isoforms; standard antibody epitope principle). Map the catalog antibody immunogen against isoforms 1–4 before interpreting a missing cell population as true absence (UniProt Q9NR81 isoforms; standard IHC practice). The DH domain spans residues 122–304, the PH domain 291–449, and reported phosphoserines include 47 and 70 (UniProt Q9NR81 domains; modified residues). Epitope accessibility after retrieval is empirical, so compare serial sections using a second independently mapped epitope when possible (standard IHC practice).

How can IF help assess an ambiguous ARHGEF3 IHC pattern?

As a secondary IF check, multiplex ARHGEF3 with a neuronal marker in cerebral cortex, where neuronal staining is reported high but uncertain (HPA tissue IHC). Choose a spectrally separated red or far-red fluorophore after checking tissue autofluorescence and single-stain controls (standard IF practice). ARHGEF3 has no transmembrane segment and is annotated cytoplasmic, so permeabilise fixed cells to expose the cytosolic epitope, then titrate detergent to preserve morphology (UniProt Q9NR81 topology; subcellular; standard IF practice). Check cell-level colocalisation against the approved cytosolic IF localisation, with no-primary and single-color controls (HPA subcellular; standard IF practice).

How can I separate ARHGEF3 staining from chromogenic background?

Block endogenous peroxidase before DAB development, then include a no-primary section to reveal endogenous enzyme activity or secondary reagent binding (standard IHC practice). Use protein blocking and wash stringency consistently, especially when comparing densely cellular regions against stromal areas (standard IHC practice). The selected tonsil image used primary antibody 1:200 overnight at 4°C and secondary antibody 1:200 for 30 minutes at room temperature; titrate around these conditions if diffuse color obscures cellular boundaries (caption A09012-1; standard IHC practice). Exclude folds, section edges and necrotic deposits from scoring, and document the excluded area (standard IHC practice).

How should I quantify ARHGEF3 in heterogeneous paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell compartment and eligible cell population before scoring, because UniProt places ARHGEF3 in cytoplasm while tissue IHC reports uncertain nuclear staining (UniProt Q9NR81 subcellular; HPA tissue IHC). Use an H-score from 0–300 based on intensity categories and their percentage of positive cells, or report percent positive cells separately (standard IHC practice). For sparse positive populations, count stained cells per mm² of viable tissue and normalise each result to the number of eligible cells or viable area (standard IHC practice). Keep thresholds, magnification and observer rules fixed across batches, and report compartment-specific scores (standard IHC practice).

Which ARHGEF3 staining patterns warrant skepticism in IHC?

Treat crisp cytoplasmic staining in morphologically intact cells as more consistent with the approved cytosolic localisation than diffuse nuclear-only deposits (UniProt Q9NR81 subcellular; HPA subcellular). However, HPA tissue IHC reports nuclear expression with uncertain reliability, so a nuclear result needs independent confirmation before biological interpretation (HPA tissue IHC). Compare stained cell identity with reported populations such as cerebral cortex neurons or bone marrow hematopoietic cells, while remembering those HPA observations are uncertain (HPA tissue IHC). Reject edge effects, necrosis-associated pigment and residual endogenous peroxidase when they persist in no-primary or processing controls (standard IHC practice).

Boster reagents

Best ARHGEF3 / Rho guanine nucleotide exchange factor 3 IHC Antibodies

A09012-1 has a paraffin-section IHC image from human tonsil (image caption). IF is listed for a human-, mouse- and rat-reactive antibody, but no IF image is supplied (catalog applications/reactivity; IF image alts).

Real IHC data Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 30min).

Anti-XPLN ARHGEF3 Antibody

Cat # A09012-1

View product →

A09012-1 is shown staining paraffin-embedded human tonsil by IHC, with antibody diluted 1:200 and Tris-EDTA retrieval at pH 9.0 (image caption). A09012-1 also lists IF and human, mouse and rat reactivity; no IF specimen or image is provided (catalog applications/reactivity; IF image alts).

Which to pick: For tissue IHC, choose A09012-1 for the demonstrated paraffin-section use; the fixative is unreported (image caption). For IF/ICC, A09012-1 lists IF, while ICC use and an IF image are unreported (catalog applications; IF image alts). For work across species, A09012-1 lists human, mouse and rat reactivity, although its IHC image shows only human tissue and clonality is unreported (catalog reactivity/clone; image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9NR81 (ARHG3_HUMAN, Rho guanine nucleotide exchange factor 3).
Human Protein Atlas. ARHGEF3 tissue IHC expression (reliability: Uncertain).
Human Protein Atlas. ARHGEF3 subcellular location (ICC-IF): Localized to the cytosol..
Human Protein Atlas. ARHGEF3 antibody validation summary (2 antibodies).
Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 — PMC13335697.
The putative tumor activator ARHGEF3 promotes nasopharyngeal carcinoma cell pathogenesis by inhibiting cellular apoptosis. Oncotarget 2016 — PMC5041948.
SNP in human ARHGEF3 promoter is associated with DNase hypersensitivity, transcript level and platelet function, and Arhgef3 KO mice have increased mean platelet volume. PloS one 2017 — PMC5441597.
PubMed PMID:10873612 — UniProt-cited evidence.
PubMed PMID:11230166 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.